DNLI - Denali Kapitalizatsiyaning sotish hajmiga nisbati
GURU.Markets grafigidagi Denali Therapeutics (DNLI) uchun P/S koeffitsiyenti dinamikasi sinovlarning tashqi pudratchilar orqali autsorsing qilinganiga asoslangan bo'lib, 141.70 qiymati joriy metrikani aks ettiradi. O'sish qon-miya to'sig'ini yengib o'tish uchun sog'liqni saqlash gigantlari bilan hamkorlik qilish orqali ta'minlanmoqda, ilmiy pipeline muvaffaqiyati esa biomateriallar uchun sovuq zanjir logistikasiga qat'iy rioya qilinishi bilan kafolatlanadi.
Denali Therapeutics Inc (DNLI) kompaniyasining tahliliy kesimlari
- aksiya narxi va baholash bo'yicha konsensus prognoz:
- bozor kapitallashuvi statistikasi:
- balans kapitallashuvi haqida ma'lumot:
- qarz majburiyatlari va likvidlik statistikasi:
Barcha qarzlarning o‘z mablag‘lariga nisbati Denali Therapeutics|DNLI - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati Denali Corp|DNLI - Kompaniya qarzlari|Qarzlarning balans kapitallashuviga nisbati Denali Therapeutics Inc|DNLI - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz Denali Therapeutics|Tezkor likvidlik koeffitsiyenti denalitherapeutics.com
- foyda va qiymat multiplikatorlari haqida ma'lumot:
DNLI - Sof daromad|Kelajakdagi sof foyda Denali Therapeutics|DNLI - P/E multiplikatori|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Denali|DNLI - PEG multiplikatori|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti Denali Therapeutics Inc|DNLI - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Denali Therapeutics|DNLI - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun foydaning yillik o'sishi denalitherapeutics.com|DNLI - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun foydaning prognoz qilingan o'sish sur'ati Denali Therapeutics
- emitentning tushumi va sotuvlari tafsilotlari:
Kompaniyaning fundamental tahlili:denalitherapeutics.com - DNLI
P/S koeffitsiyenti biznesning bozor qiymatini uning yillik daromadiga nisbatan aks ettiradi va joriy kapitalizatsiyani tarixiy ekstremumlar bilan solishtirish orqali aktivning haddan tashqari qimmat baholanganligini baholash imkonini beradi. Sotuvlar nisbatidagi narx koeffitsiyentini tahlil qilish orqali investor qon-miya to'sig'i dori yetkazib berish platformasining salohiyati va strategik hamkorlardan kutilayotgan to'lovlarni hisobga olgan holda Denali Therapeutics (DNLI) kompaniyasining baholanishi adolatli ekanligini aniqlashi mumkin.
Raqobatdosh kompaniyalar
BIIB (biogen.com) - Bozor kapitallashuvining daromadga nisbati|Neurocrine Biosciences, Inc. - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati RGC (Regencell Bioscience Ltd)|Axsome Therapeutics Inc - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati ACAD (ACADIA Corp)|XENE: P/S multiplikatori|Sotuvga nisbatan narx vikingtherapeutics.com (VKTX)|Narxning daromadga nisbati Supernus|CPRX: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori HRMY|P/S multiplikatori Biohaven Corp (BHVN)|Narxning daromadga nisbati Amylyx Pharmaceuticals AMLX|TRVI (trevitherapeutics.com) - Narxning sotuvga nisbati|Praxis Precision Medicines, Inc. - P/S multiplikatori|Sotuvga nisbatan narx Anavex|CBLL (CeriBell Corp) - Kapitalizatsiyaning daromadga nisbati|Prothena Corp (PRTA) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati ALEC|ANNX (annexonbio.com) - Kapitalizatsiyaning sotish hajmiga nisbati|P/S multiplikatori OMER|Narx/daromad koeffitsiyenti Neurogene Inc|P/S multiplikatori ACIU (AC Immune Corp)|VYGR - Kapitalizatsiyaning daromadga nisbati|NMRA - Narxning daromadga nisbati|Narx/daromad koeffitsiyenti scilexholding.com SCLX|TVGN: P/S multiplikatori|Kapitalizatsiya va daromad nisbati ACOG|Narxning daromadga nisbati Cognition Therapeutics, Inc.|Kapitalizatsiya va daromad nisbati IKT (Inhibikase Pharma)|Narxning daromadga nisbati Cassava Sciences, Inc. (SAVA)|Narxning daromadga nisbati ASRT (assertiotx.com)|P/S multiplikatori COYA (Coya Therapeutics)|Narx/daromad koeffitsiyenti VistaGen Therapeutics, Inc. (VTGN)|OVID - Narxning daromadga nisbati|ABOS (Acumen Pharmaceuticals, Inc) - Kapitalizatsiya va daromad nisbati|CRVO: P/S multiplikatori|Sotuvga nisbatan narx Alterity Therapeutics Limited (ATHE)|Kapitalizatsiyaning daromadga nisbati CLNN|P/S multiplikatori PepGen Corp|Narxning daromadga nisbati Jupiter Neurosciences (JUNS)|RLMD (Relmada Corp) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Annovis Bio, Inc. ANVS|Grace Therapeutics Inc (GRCE) - Sotuvga nisbatan narx|Firefly Neuroscience - P/S multiplikatori|KLTO (Klotho Neurosciences Inc) - Kapitalizatsiya va daromad nisbati|NRSN: P/S multiplikatori|Sotuvga nisbatan narx Reviva Pharmaceuticals, Inc. (RVPH)|Narxning daromadga nisbati MetaVia Inc.|Kapitalizatsiya va daromad nisbati NRXS (neuraxis.com)|P/S multiplikatori HSDT|P/S multiplikatori passagebio.com (PASG)|Narxning daromadga nisbati Neuphoria Therapeutics NEUP|Minerva - Narxning daromadga nisbati|Athira Pharma, Inc. - P/S multiplikatori|Narx/daromad koeffitsiyenti addextherapeutics.com ADXN|ALZN (alzamend.com) - Kapitalizatsiyaning daromadga nisbati|Cyclerion Therapeutics, Inc. - Bozor kapitallashuvining daromadga nisbati|Kapitalizatsiyaning daromadga nisbati PTIX|KTTA (Pasithea) - Kapitalizatsiyaning sotish hajmiga nisbati|P/S multiplikatori CRGT|ATXI (avenuetx.com) - Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori BCLI (BrainStorm Cell Therapeutics)|Cara Therapeutics Inc. (CARA) - Sotuvga nisbatan narx|CHRO - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati ELYM (Eliem Therapeutics)|ITCI: P/S multiplikatori|longboardpharma.com (LBPH) - P/S multiplikatori|Narxning daromadga nisbati Marinus Pharmaceuticals, Inc.|NKGen Biotech Inc - Narxning sotuvga nisbati|P/S multiplikatori NRBO|SAGE - Sotuvga nisbatan narx|Synaptogenix, Inc. - Kapitalizatsiyaning daromadga nisbati|P/S multiplikatori trevena.com TRVN|VIGL: Kapitalizatsiyaning daromadga nisbati|anewmeds.com - Kapitalizatsiyaning sotish hajmiga nisbati|CERE: P/S multiplikatori
